GLP-1 & Metabolic Peptides Research Hub¶
Overview¶
GLP-1 receptor agonists and metabolic peptides represent the most commercially and scientifically significant category in peptide research. From glucose homeostasis to body weight regulation, these peptides target evolutionarily conserved metabolic pathways with increasing precision.
HK Peptides Worldwide supplies 7 GLP-1 and metabolic research peptides across 20+ SKU configurations — manufacturer-direct, HPLC-verified, with batch-specific COA documentation.
The Incretin System¶
The incretin effect describes the observation that oral glucose elicits a greater insulin response than intravenous glucose. Two key incretin hormones mediate this effect:
| Hormone | Source | Receptor | Primary Actions |
|---|---|---|---|
| GLP-1 (Glucagon-Like Peptide-1) | Intestinal L-cells | GLP-1R | Insulin secretion (glucose-dependent), glucagon suppression, gastric emptying delay, satiety |
| GIP (Glucose-dependent Insulinotropic Peptide) | Intestinal K-cells | GIPR | Insulin secretion, lipid metabolism, bone formation |
Native GLP-1 has a half-life of ~2 minutes due to rapid DPP-4 cleavage. All therapeutic-grade GLP-1 analogs require DPP-4 resistance engineering to achieve meaningful exposure duration.
Product Comparison: GLP-1 Receptor Agonists¶
| Parameter | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| CAS | 910463-68-2 | 2023788-19-2 | 2381089-83-2 |
| Receptors | GLP-1R | GIPR + GLP-1R | GIPR + GLP-1R + GCGR |
| MW | ~4,113.6 Da | ~4,813.5 Da | ~4,845.5 Da |
| DPP-4 Resistance | Aib⁸ substitution | Engineered | Engineered |
| Half-Life Extension | C18 fatty diacid (albumin binding) | C20 fatty diacid | C20 fatty diacid |
| Synthesis Complexity | High | Very High | Complex |
| Research Stage | Most studied | Advanced | Phase 2/3 |
Semaglutide¶
The foundation GLP-1R agonist. Two key structural modifications — Aib⁸ for DPP-4 protection and C18 fatty diacid at Lys²⁶ for albumin binding — produce a ~7-day half-life. The most extensively characterized peptide in the GLP-1 category.
Tirzepatide¶
The first dual incretin agonist to demonstrate superiority over GLP-1 monotherapy. Co-activating GIPR and GLP-1R produces enhanced metabolic effects including greater weight reduction and improved glycemic control.
Retatrutide¶
Triple receptor agonism (GIPR + GLP-1R + GCGR) represents the frontier of metabolic peptide research. GCGR activation increases energy expenditure through hepatic mechanisms, adding a thermogenic dimension to incretin-based therapy.
Complementary Metabolic Peptides¶
Cagrilintide¶
Long-acting amylin analog. Amylin is co-secreted with insulin from pancreatic β-cells and contributes to satiety signaling and gastric emptying. Cagrilintide + Semaglutide combination (CagriSema) is under investigation for enhanced weight management.
AOD-9604¶
Synthetic hGH C-terminal fragment (amino acids 177-191). Retains the lipolytic domain of growth hormone without GHR binding — meaning fat mobilization occurs without IGF-1 elevation, insulin resistance, or growth-promoting activity.
MOTS-c¶
Mitochondrial-derived peptide encoded within the 12S rRNA region. Regulates metabolic flexibility and insulin sensitivity through AMPK activation and folate cycle modulation. Represents an emerging class of mitochondrial signaling peptides.
Tesamorelin¶
GHRH analog that stimulates pituitary GH secretion. Used in research contexts involving visceral adipose tissue reduction and body composition studies.
Research Framework¶
Key Assays for Metabolic Peptide Research¶
| Assay | Target | Readout |
|---|---|---|
| GLP-1R cAMP assay | Receptor activation | EC₅₀, efficacy |
| Glucose tolerance test (GTT) | In vivo glucose handling | Blood glucose AUC |
| Food intake measurement | Appetite/satiety | Cumulative food intake |
| Body composition (DEXA/MRI) | Fat/lean mass | % change |
| Gastric emptying assay | GI motility | Time to 50% emptying |
| Energy expenditure | Metabolic rate | O₂ consumption, CO₂ production |
Quality Specifications¶
All metabolic peptides from HK Peptides Worldwide meet:
- ≥99% HPLC purity — C18 reverse-phase, 214/220 nm
- ESI-MS molecular weight confirmation — ±1.0 Da
- Linker integrity verification — HPLC-ELSD or LC-MS/MS for fatty acid-conjugated peptides
- Batch-specific COA — included with every order